Repatha SureClick 140 mg Injection

Description

Repatha SureClick 140 mg/mL Injection is a prescription lipid-lowering medicine containing evolocumab, a monoclonal antibody that inhibits PCSK9. By blocking PCSK9, evolocumab helps the liver remove more LDL cholesterol from the bloodstream. It is used alongside dietary measures and, where appropriate, other cholesterol-lowering medicines for eligible patients. Depending on the approved local product information, it may also be prescribed to reduce the risk of certain major cardiovascular events in adults at increased risk. SRK Pharma supports pharmaceutical sourcing and international distribution enquiries, subject to product availability, required authorisations, and destination-country regulations. Healthcare professionals and eligible purchasing organisations can contact our team for product specifications, quotations, and applicable supply documentation.

Uses of Repatha SureClick 140 mg/mL Injection

• Helps lower elevated LDL cholesterol levels.
• Used in eligible patients with primary hypercholesterolaemia.
• Used in certain patients with inherited high cholesterol, including heterozygous familial hypercholesterolaemia.
• May be used with other lipid-lowering therapies in patients who require additional cholesterol reduction.
• May help reduce the risk of specified cardiovascular events in eligible adults, according to the local approved label.

Benefits in Treatment

• LDL cholesterol reduction: Helps lower levels of LDL cholesterol in the blood.
• Additional treatment option: Can be used alongside diet and other lipid-lowering medicines when prescribed.
• Targeted mechanism: Blocks PCSK9 to support the liver’s removal of LDL cholesterol.
• Cardiovascular risk reduction: May reduce certain major cardiovascular risks in appropriately selected patients, according to the approved indication.
• Convenient delivery system: The prefilled SureClick autoinjector provides a ready-to-use administration format for prescribed subcutaneous doses.

Treatment response varies between patients. Repatha does not replace a heart-healthy diet, lifestyle measures, or other prescribed medicines unless the treating clinician changes the treatment plan.

Side Effects of Repatha SureClick 140 mg/mL Injection

Possible side effects include:

• Common cold-like symptoms, including a runny nose or sore throat.
• Upper respiratory tract infections.
• Back pain.
• Joint or muscle pain.
• Redness, pain, bruising, or swelling at the injection site.
• Headache or nausea.
• Allergic reactions, including rash or hives.

Serious warning: Severe allergic reactions, including swelling of the face, lips, tongue, or throat and difficulty breathing, require emergency medical attention.

Inform your healthcare professional about any allergies, other medicines, pregnancy or breastfeeding, and relevant medical conditions before treatment.

Quick Tips

1. Use Repatha only as prescribed by your healthcare professional.
2. Follow the official instructions supplied with the SureClick autoinjector.
3. Store the medicine in the refrigerator at 2°C–8°C and protect it from light.
4. Never freeze or shake the autoinjector.
5. Inspect the solution and packaging before use; follow the product leaflet for any abnormal appearance.
6. Rotate injection sites and use only the approved subcutaneous injection areas.
7. Do not reuse or share the single-use autoinjector.
8. Maintain scheduled cholesterol tests and follow-up appointments.
9. Ask your healthcare professional what to do if you miss a dose.

To Order Email: oder@srkpharma.com | Contact SRK Pharma for product availability, pack-size confirmation, quotations, and eligible international supply enquiries, subject to applicable regulations.

Patient Assistance Program (PAP) – We also support Patient Assistance Programs (PAPs) and Patient Named Programs, helping eligible patients access required medicines through a patient-focused and streamlined process. We support patients and healthcare partners with product sourcing, documentation, order coordination, and delivery assistance, subject to applicable program requirements and country regulations. We support medicine supply through PAP and Patient Named Programs across countries including the USA, UK, Canada, Australia, India, Brazil, Nigeria, South Africa, UAE, Saudi Arabia, Germany, France, Italy, Spain, Singapore, Malaysia, and other international markets, subject to local authorisations and applicable requirements. Our goal is to make access to essential medicines simpler, reliable, and patient-focused, while supporting patients and healthcare partners throughout the supply process.

Note: PAP participation, product eligibility, and supply arrangements are subject to program approval, product availability, and applicable local laws and regulations.